Abstract
To assess the value of T2* dynamic-susceptibility contrast MRI (DSC-MRI) and diffusion-weighted imaging (DWI) to predict the glioblastoma relapse sites after chemoradiation. From a cohort of 44 patients, primarily treated with radiotherapy (60 Gy) and concomitant temozolomide for glioblastoma, who were included in the reference arm of a prospective clinical trial (NCT01507506), 15 patients relapsed and their imaging data were analyzed. All patients underwent anatomical MRI, DSC-MRI and DWI before radiotherapy and every 2 months thereafter until relapse. Voxels within the sites of relapse were correlated with their perfusion and/or diffusion abnormality (PDA) pretreatment status after rigid co-registration. The relative cerebral blood volume (rCBV) and apparent diffusion coefficient (ADC) were used as biomarkers. Several PDA areas were thresholded: hyperperfused voxels using a 1.75 fixed rCBV threshold (HPt); hypoperfused (hPg) and hyperperfused (HPg) voxels using a histogram-based Gaussian method; diffusion-restricted voxels (DRg); and HPg voxels with diffusion restriction (HPg&DRg). Two sets of voxels (2,459,483 and 2,073,880) were analyzed according to these thresholding methods. Positive predictive values (PPV) of PDA voxels were low (between 9.5 and 31.9 %). The best PPV was obtained with HPg&DRg voxels within the FLAIR hyperintensity, as 18.3 % of voxels without initial PDA were within relapse sites, versus 31.9 % with initial PDA (p <0.0001). This prospective study suggests that DSC and/or DWI-MRI do not predict the glioblastoma relapse sites. However, further investigations with new methodological approaches are needed to better understand the role of these modalities in the prediction of glioblastoma relapse sites.
Original language | English |
---|---|
Pages (from-to) | 1-12 |
Number of pages | 12 |
Journal | Journal of Neuro-Oncology |
DOIs | |
Publication status | Accepted/In press - Aug 8 2016 |
Externally published | Yes |
Fingerprint
Keywords
- Diffusion weighted magnetic resonance imaging
- Glioblastoma
- Perfusion weighted magnetic resonance imaging
- Sites of relapse
- Voxel-based quantification
ASJC Scopus subject areas
- Medicine(all)
- Oncology
- Neurology
- Clinical Neurology
- Cancer Research
Cite this
Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation? / Khalifa, Jonathan; Tensaouti, Fatima; Lotterie, Jean Albert; Catalaa, Isabelle; Chaltiel, Leonor; Benouaich-Amiel, Alexandra; Gomez-Roca, Carlos; Noël, Georges; Truc, Gilles; Péran, Patrice; Berry, Isabelle; Sunyach, Marie Pierre; Charissoux, Marie; Johnson, Corinne; Cohen-Jonathan Moyal, Elizabeth; Laprie, Anne.
In: Journal of Neuro-Oncology, 08.08.2016, p. 1-12.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
AU - Khalifa, Jonathan
AU - Tensaouti, Fatima
AU - Lotterie, Jean Albert
AU - Catalaa, Isabelle
AU - Chaltiel, Leonor
AU - Benouaich-Amiel, Alexandra
AU - Gomez-Roca, Carlos
AU - Noël, Georges
AU - Truc, Gilles
AU - Péran, Patrice
AU - Berry, Isabelle
AU - Sunyach, Marie Pierre
AU - Charissoux, Marie
AU - Johnson, Corinne
AU - Cohen-Jonathan Moyal, Elizabeth
AU - Laprie, Anne
PY - 2016/8/8
Y1 - 2016/8/8
N2 - To assess the value of T2* dynamic-susceptibility contrast MRI (DSC-MRI) and diffusion-weighted imaging (DWI) to predict the glioblastoma relapse sites after chemoradiation. From a cohort of 44 patients, primarily treated with radiotherapy (60 Gy) and concomitant temozolomide for glioblastoma, who were included in the reference arm of a prospective clinical trial (NCT01507506), 15 patients relapsed and their imaging data were analyzed. All patients underwent anatomical MRI, DSC-MRI and DWI before radiotherapy and every 2 months thereafter until relapse. Voxels within the sites of relapse were correlated with their perfusion and/or diffusion abnormality (PDA) pretreatment status after rigid co-registration. The relative cerebral blood volume (rCBV) and apparent diffusion coefficient (ADC) were used as biomarkers. Several PDA areas were thresholded: hyperperfused voxels using a 1.75 fixed rCBV threshold (HPt); hypoperfused (hPg) and hyperperfused (HPg) voxels using a histogram-based Gaussian method; diffusion-restricted voxels (DRg); and HPg voxels with diffusion restriction (HPg&DRg). Two sets of voxels (2,459,483 and 2,073,880) were analyzed according to these thresholding methods. Positive predictive values (PPV) of PDA voxels were low (between 9.5 and 31.9 %). The best PPV was obtained with HPg&DRg voxels within the FLAIR hyperintensity, as 18.3 % of voxels without initial PDA were within relapse sites, versus 31.9 % with initial PDA (p <0.0001). This prospective study suggests that DSC and/or DWI-MRI do not predict the glioblastoma relapse sites. However, further investigations with new methodological approaches are needed to better understand the role of these modalities in the prediction of glioblastoma relapse sites.
AB - To assess the value of T2* dynamic-susceptibility contrast MRI (DSC-MRI) and diffusion-weighted imaging (DWI) to predict the glioblastoma relapse sites after chemoradiation. From a cohort of 44 patients, primarily treated with radiotherapy (60 Gy) and concomitant temozolomide for glioblastoma, who were included in the reference arm of a prospective clinical trial (NCT01507506), 15 patients relapsed and their imaging data were analyzed. All patients underwent anatomical MRI, DSC-MRI and DWI before radiotherapy and every 2 months thereafter until relapse. Voxels within the sites of relapse were correlated with their perfusion and/or diffusion abnormality (PDA) pretreatment status after rigid co-registration. The relative cerebral blood volume (rCBV) and apparent diffusion coefficient (ADC) were used as biomarkers. Several PDA areas were thresholded: hyperperfused voxels using a 1.75 fixed rCBV threshold (HPt); hypoperfused (hPg) and hyperperfused (HPg) voxels using a histogram-based Gaussian method; diffusion-restricted voxels (DRg); and HPg voxels with diffusion restriction (HPg&DRg). Two sets of voxels (2,459,483 and 2,073,880) were analyzed according to these thresholding methods. Positive predictive values (PPV) of PDA voxels were low (between 9.5 and 31.9 %). The best PPV was obtained with HPg&DRg voxels within the FLAIR hyperintensity, as 18.3 % of voxels without initial PDA were within relapse sites, versus 31.9 % with initial PDA (p <0.0001). This prospective study suggests that DSC and/or DWI-MRI do not predict the glioblastoma relapse sites. However, further investigations with new methodological approaches are needed to better understand the role of these modalities in the prediction of glioblastoma relapse sites.
KW - Diffusion weighted magnetic resonance imaging
KW - Glioblastoma
KW - Perfusion weighted magnetic resonance imaging
KW - Sites of relapse
KW - Voxel-based quantification
UR - http://www.scopus.com/inward/record.url?scp=84981156508&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84981156508&partnerID=8YFLogxK
U2 - 10.1007/s11060-016-2232-8
DO - 10.1007/s11060-016-2232-8
M3 - Article
AN - SCOPUS:84981156508
SP - 1
EP - 12
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
SN - 0167-594X
ER -